Cargando…
Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study
The success of autologous stem cell transplantation (ASCT) for hematologic malignancy is limited largely by a high relapse rate. It is postulated that IL-2 administered after ASCT may eliminate minimal residual disease and thereby reduce relapses. A phase I/II study was performed to identify a regim...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
1997
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092324/ https://www.ncbi.nlm.nih.gov/pubmed/9052908 http://dx.doi.org/10.1038/sj.bmt.1700687 |